<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3363606</article-id><article-id pub-id-type="publisher-id">cc10795</article-id><article-id pub-id-type="doi">10.1186/cc10795</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Short-term hemodynamic effects of nebivolol in acute decompensated heart failure: a randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Puig</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Ochiai</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Cardoso</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Vieira</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Brancalhao</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Lima</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Pereira Barretto</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Hospital Auxiliar de Cotoxo - InCor - HCFMUSP, S&#x000e3;o Paulo, Brazil</aff><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2012</year></pub-date><volume>16</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">32nd International Symposium on Intensive Care and Emergency Medicine</named-content></supplement><fpage>P188</fpage><lpage>P188</lpage><permissions><copyright-statement>Copyright &#x000a9;2012 Puig et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Puig et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/16/S1/P188"/><conference><conf-date>20-23 March 2012</conf-date><conf-name>32nd International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Acute decompensation heart failure in patients in use of &#x003b2;-blocker has become frequent and maintenance of this drug remains controversial, mainly in low cardiac output. Nitric-oxide-dependent vasodilation of nebivolol could be useful in this situation.</p></sec><sec sec-type="methods"><title>Methods</title><p>We evaluated hospitalized patients with acute decompensated heart failure, NYHA IV, EF &#x0003c;0.45, in use of dobutamine and carvedilol. Intervention: patients were randomly assigned to carvedilol maintenance or exchange to nebivolol according to Table <xref ref-type="table" rid="T1">1</xref>. Hemodynamic parameters were compared using a noninvasive model flow technique (Nexfin<sup>&#x000ae;</sup>; BMEYE), 24 hours before, 6 and 24 hours after the randomization. <italic>P </italic>&#x0003c; 0.05 was significant.</p><table-wrap id="T1" position="float"><label>Table 1</label><table frame="hsides" rules="groups"><thead><tr><th align="center">Carvedilol</th><th align="center">Nebivolol</th></tr></thead><tbody><tr><td align="center">6.25 mg/bid</td><td align="center">2.5 mg/qd</td></tr><tr><td align="center">12.5 mg/bid</td><td align="center">5.0 mg/qd</td></tr><tr><td align="center">25.0 mg/bid</td><td align="center">10.0 mg/qd</td></tr></tbody></table></table-wrap></sec><sec sec-type="results"><title>Results</title><p>We selected 30 patients, 75% men, age 56.0 (SD = 13.0) years, ejection fraction 23.4 (SD = 7.2)%, ischemic myocardiopathy present in 16.7%, Chagas disease in 40% and 43.3% of patients were nonischemic/non-Chagas. Baseline indexed systemic vascular resistance was 2,255.9 (SD = 792.4) dynes.second/cm<sup>5</sup>/m<sup>2</sup>, and cardiac index was 2.7 (SD = 0.6) l/minute/m. In the nebivolol group (<italic>n </italic>= 15) the indexed systemic vascular resistance reduced 0.6% and in the carvedilol group (<italic>n </italic>= 15) it reduced 5.0% in 24 hours (mean difference 4.4%; 95% CI: -12.6 to 21.4%; <italic>P </italic>= 0.513). The cardiac index maintained unchanged (<italic>P </italic>= 0.274). Comparing patients that received a high dose of nebivolol (5 to 10 mg/day) to those with a low dose (&#x0003c;5 mg/day) or carvedilol, we observed a tendency to superiority of high dose in reduction of systemic vascular resistance, although not statistically significant (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Systemic vascular resistance change: nebivolol high&#x000d7;nebivolol low or carvedilol</bold>.</p></caption><graphic xlink:href="cc10795-1"/></fig></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Short-term nebivolol use in decompensated heart failure was hemodynamically safe. Further studies should be done to clarify this matter.</p></sec></body></article>